Table 3. Univariate analyses of clinicopathologic parameters on recurrence-free and overall survival in patients with adenocarcinoma.

	Adenocarcinoma (n=222)
		Recurrence-free survival		Overall survival
Variables	N (%)	5-year rate (%)	P-value	5-year rate (%)	P-value
Age, years
As continuous variable	222 (100)		0.153		0.073
<30	5 (2.3)	80	0.250	80	0.096
30–49	141 (63.5)	89		93
>50	76 (34.2)	81		86
FIGO stage
IA2	8 (3.6%)	100	<0.001	100	<0.001
IB1–IB2	195 (87.8%)	89		92
IIA	19 (8.6%)	52		65
Histologic subtype
Mucinous	203 (16.7%)	87	0.373	90	0.425
Endometrioid	14 (1.1%)	77		84
Serou	2 (0.2%)	50		50
Mixed	3 (0.2%)	100		100
Grade of differentiation a
Well	63 (29.0)	88	0.688	90	0.532
Moderately	94 (43.3)	83		91
Poorly	60 (27.6)	87		89
Tumour size, cm
⩽2	108 (48.6)	91	0.041	95	0.033
2–4	94 (42.3)	82		85
4–6	20 (9.0)	77		90
>6	0 (0.0)	—		—
Depth of stromal invasion
⩽1/2	135 (60.8)	92	0.002	94	0.008
>1/2	87 (39.2)	78		84
Parametrial involvement
No	200 (90.1)	89	<0.001	92	<0.001
Yes	22 (9.9)	55		66
Resection margin
Negative	218 (98.2)	87	0.013	91	0.005
Positive	4 (1.8)	38		38
LVSI
No	189 (85.1)	88	0.033	92	0.026
Yes	33 (14.9)	75		80
Lymph node metastasis
No	188 (84.7)	90	<0.001	94	<0.001
Yes	34 (15.3)	66		69
Adjuvant treatment
None	159 (71.6)	89	0.003	94	<0.001
Chemotherapy	20 (9.0)	88		95
Radiation therapy	26 (11.7)	76		77
CCRT	11 (7.7)	71		70

Abbreviations: CCRT=concurrent chemoradiation therapy; FIGO=International Federation of Obstetrics and Gynecology; LVSI=lymphovascular space invasion.

^aGrade of differentiation was undetermined in 21 patients.